Total Payments
$3,820
2024 Payments
$501.71
Companies
18
Transactions
61
Medicare Patients
461
Medicare Billing
$65,042
Payment Breakdown by Category
Food & Beverage$2,638 (69.1%)
Research$1,159 (30.3%)
Education$23.09 (0.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,638 | 57 | 69.1% |
| Unspecified | $1,159 | 2 | 30.3% |
| Education | $23.09 | 2 | 0.6% |
Payments by Type
General
$2,661
59 transactions
Research
$1,159
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| TransMedics, Inc. | $1,159 | 2 | $0 (2019) |
| Gilead Sciences, Inc. | $899.56 | 8 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $594.04 | 7 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $341.42 | 16 | $0 (2019) |
| Veloxis Pharmaceuticals, Inc. | $234.24 | 5 | $0 (2021) |
| GENZYME CORPORATION | $100.00 | 1 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $71.40 | 3 | $0 (2024) |
| EISAI INC. | $62.92 | 4 | $0 (2019) |
| Merck Sharp & Dohme LLC | $54.09 | 3 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $47.59 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $501.71 | 11 | SANOFI-AVENTIS U.S. LLC ($259.95) |
| 2023 | $195.19 | 3 | SANOFI-AVENTIS U.S. LLC ($166.96) |
| 2022 | $171.17 | 3 | SANOFI-AVENTIS U.S. LLC ($140.00) |
| 2021 | $75.35 | 3 | Veloxis Pharmaceuticals, Inc. ($30.39) |
| 2020 | $242.92 | 3 | Gilead Sciences, Inc. ($124.91) |
| 2019 | $1,592 | 12 | TransMedics, Inc. ($1,159) |
| 2018 | $374.12 | 10 | Gilead Sciences, Inc. ($124.90) |
| 2017 | $667.61 | 16 | Gilead Sciences Inc ($374.42) |
All Payment Transactions
61 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), DIFICID | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/18/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $18.35 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: IMMUNOLOGY | ||||||
| 06/13/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $41.18 | General |
| Category: Rare Disease | ||||||
| 06/03/2024 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | In-kind items and services | $91.21 | General |
| 05/28/2024 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | In-kind items and services | $43.13 | General |
| 05/01/2024 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | In-kind items and services | $125.61 | General |
| 03/22/2024 | Haemonetics Corporation | TEG6S HEMOSTASIS SYSTEM (Device) | Food and Beverage | In-kind items and services | $47.25 | General |
| Category: DEVICES | ||||||
| 03/15/2024 | One Lambda, Inc. | — | Food and Beverage | Cash or cash equivalent | $45.43 | General |
| 02/16/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $28.47 | General |
| Category: Nephrology | ||||||
| 02/02/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/14/2023 | Takeda Pharmaceuticals U.S.A., Inc. | LIVTENCITY (Drug) | Food and Beverage | In-kind items and services | $28.23 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2023 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | In-kind items and services | $77.65 | General |
| 06/02/2023 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | In-kind items and services | $89.31 | General |
| 07/28/2022 | ClearPoint Neuro, Inc. | CLEARPOINT (Device) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: Neurology | ||||||
| 06/04/2022 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | In-kind items and services | $140.00 | General |
| 01/13/2022 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/19/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $17.83 | General |
| 10/28/2021 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | In-kind items and services | $27.13 | General |
| 03/11/2021 | Veloxis Pharmaceuticals, Inc. | Envarsus (Drug) | Food and Beverage | In-kind items and services | $30.39 | General |
| Category: Immunosuppresant | ||||||
| 03/12/2020 | Allergan, Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/09/2020 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $100.00 | General |
| 01/06/2020 | Gilead Sciences, Inc. | Harvoni (Drug) | Food and Beverage | In-kind items and services | $124.91 | General |
| Category: HCV | ||||||
| 11/20/2019 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $16.50 | General |
| Category: Oncology | ||||||
| 07/15/2019 | Gilead Sciences, Inc. | Harvoni (Drug) | Food and Beverage | In-kind items and services | $124.91 | General |
| Category: HCV | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PROTECT LIVER | TransMedics, Inc. | $926.87 | 1 |
| LIVER RESARCH | TransMedics, Inc. | $231.72 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 44 | 60 | $30,652 | $9,020 |
| 2022 | 4 | 63 | 80 | $55,195 | $13,506 |
| 2021 | 5 | 92 | 143 | $70,572 | $17,422 |
| 2020 | 8 | 262 | 759 | $98,574 | $25,094 |
Total Patients
461
Total Services
1,042
Medicare Billing
$65,042
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 33 | 49 | $24,073 | $6,979 | 29.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $6,579 | $2,041 | 31.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 23 | 39 | $19,108 | $5,458 | 28.6% |
| 49324 | Insertion of abdominal cavity tube using an endoscope | Facility | 2022 | 11 | 11 | $15,726 | $3,400 | 21.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 18 | 18 | $10,736 | $2,846 | 26.5% |
| 49422 | Removal of abdominal cavity tube | Facility | 2022 | 11 | 12 | $9,624 | $1,803 | 18.7% |
| 50200 | Needle biopsy of kidney, accessed through the skin | Office | 2021 | 15 | 16 | $35,286 | $7,542 | 21.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 29 | 46 | $22,331 | $6,685 | 29.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 16 | 20 | $7,014 | $2,244 | 32.0% |
| 76942 | Ultrasonic guidance imaging supervision and interpretation for insertion of needle | Office | 2021 | 16 | 17 | $5,370 | $870.74 | 16.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Facility | 2021 | 16 | 44 | $572.00 | $79.20 | 13.8% |
| 50200 | Needle biopsy of kidney, accessed through the skin | Office | 2020 | 14 | 14 | $30,412 | $6,915 | 22.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 32 | 55 | $21,684 | $6,574 | 30.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 21 | 31 | $9,122 | $2,700 | 29.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 30 | $8,293 | $2,638 | 31.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 13 | 13 | $7,234 | $2,302 | 31.8% |
| 49422 | Removal of abdominal cavity catheter | Facility | 2020 | 13 | 13 | $10,360 | $1,975 | 19.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Facility | 2020 | 145 | 591 | $7,683 | $1,386 | 18.0% |
| 76942 | Ultrasonic guidance imaging supervision and interpretation for insertion of needle | Office | 2020 | 12 | 12 | $3,787 | $603.19 | 15.9% |
About Dr. Christopher Marsh, M.D
Dr. Christopher Marsh, M.D is a Urology healthcare provider based in La Jolla, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023098043.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Marsh, M.D has received a total of $3,820 in payments from pharmaceutical and medical device companies, with $501.71 received in 2024. These payments were reported across 61 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($2,638).
As a Medicare-enrolled provider, Marsh has provided services to 461 Medicare beneficiaries, totaling 1,042 services with total Medicare billing of $65,042. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Other Specialties Transplant Surgery
- Location La Jolla, CA
- Active Since 01/17/2006
- Last Updated 11/13/2019
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1023098043
Products in Payments
- Organ Care System (Device) $1,159
- Harvoni (Drug) $874.05
- Nexavar (Drug) $321.29
- Envarsus XR (SP) (Drug) $119.26
- Envarsus (Drug) $80.39
- Lenvima (Drug) $62.92
- PREVYMIS (Drug) $54.09
- LIVTENCITY (Drug) $53.57
- TEG6S HEMOSTASIS SYSTEM (Device) $47.25
- IQIRVO (Drug) $41.18
- Envarsus XR (Drug) $34.59
- TARPEYO (Drug) $28.47
- UCERIS (Drug) $28.27
- Wako HCC Biomarker(s) DCP and AFP-L3 (Device) $25.04
- Stivarga (Drug) $20.13
- OCA (Drug) $19.61
- XIFAXAN (Drug) $19.32
- AVYCAZ (Drug) $18.01
- CLEARPOINT (Device) $16.92
- OCALIVA (Drug) $14.25
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in La Jolla
Dr. Jordan Siegel, Md, MD
Urology — Payments: $91,085
Urology $91,085
Edward Cohen, M.d, M.D
Urology — Payments: $54,577
Urology $54,577
Ramdev Konijeti, M.d, M.D
Urology — Payments: $18,412
Urology $18,412
Philip Butler, M.d, M.D
Urology — Payments: $13,773
Urology $13,773
Dr. Alyssa Yee, Md, MD
Urology — Payments: $10,395
Urology $10,395
Dr. Benjamin Yuh, M.d, M.D
Urology — Payments: $8,696
Urology $8,696